Dallas Biotech Patents Gene-Edited Therapy to Combat Deadly Superbugs

Dallas, Friday, 12 June 2026.
LyticGen’s newly patented gene-edited therapy targets MRSA, addressing a critical gap since no new antibiotics have been approved in decades for a superbug causing 10,000 annual US deaths.